Literature DB >> 26791847

Challenges and Opportunities for Immunotherapies in Gynecologic Cancers.

Jung-min Lee, S Percy Ivy, Elise C Kohn.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26791847

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  4 in total

1.  Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Authors:  Jung-Min Lee; Ashley Cimino-Mathews; Cody J Peer; Alexandra Zimmer; Stanley Lipkowitz; Christina M Annunziata; Liang Cao; Maria I Harrell; Elizabeth M Swisher; Nicole Houston; Dana-Adriana Botesteanu; Janis M Taube; Elizabeth Thompson; Aleksandra Ogurtsova; Haiying Xu; Jeffers Nguyen; Tony W Ho; William D Figg; Elise C Kohn
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

2.  Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.

Authors:  Erika J Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R Nair; Yingmiao Liu; Elizabeth M Swisher; James W Hodge; Andrew B Nixon; Erin Nichols; Mohammad H Bagheri; Elliott Levy; Marc R Radke; Stanley Lipkowitz; Christina M Annunziata; Janis M Taube; Seth M Steinberg; Jung-Min Lee
Journal:  Clin Cancer Res       Date:  2020-05-12       Impact factor: 12.531

3.  A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Authors:  Alexandra S Zimmer; Erin Nichols; Ashley Cimino-Mathews; Cody Peer; Liang Cao; Min-Jung Lee; Elise C Kohn; Christina M Annunziata; Stanley Lipkowitz; Jane B Trepel; Rajni Sharma; Lekha Mikkilineni; Margaret Gatti-Mays; William D Figg; Nicole D Houston; Jung-Min Lee
Journal:  J Immunother Cancer       Date:  2019-07-25       Impact factor: 13.751

4.  Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ning Ren; Leyin Zhang; Jieru Yu; Siqi Guan; Xinyang Dai; Leitao Sun; Minli Ying
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.